Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amsterdam Fistula Biology
NL-OMON26943Recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Sep 2021
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Open-label trial of mesenchymal stem cells in Crohn's disease (6 cohorts), sponsored by Amsterdam University Medical Center. Primary endpoint: Primary biomarker endpoint. Started Sep 2021; status: recruiting.
02
Drugs
mesenchymal stem cells
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NL-OMON26943.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON26943.